Results 171 to 180 of about 1,320,527 (284)

Real‐world risk factors and clinical implications of early estimated glomerular filtration rate decline after sodium‐glucose cotransporter‐2 inhibitor therapy

Journal of Diabetes Investigation, EarlyView.
Older age, atrial fibrillation, loop diuretic use, and higher eGFR variability predicted early eGFR dip. Continued SGLT2 inhibitor therapy preserved long‐term kidney function, although closer monitoring is warranted in patients receiving loop diuretics. ABSTRACT Aim To assess the prevalence, risk factors, estimated glomerular filtration rate trajectory,
Jangwook Lee, Dayoung Kang, Kyoung‐Ah Kim, Han Seok Choi, Soomin Jo, Joeun Kim, Jae Yoon Park, Seung Eun Lee   +7 more
wiley   +1 more source

Effects of esaxerenone add‐on therapy versus angiotensin II receptor blocker dose escalation on albuminuria and blood pressure in hypertensive patients with type 2 diabetes: An exploratory randomized study

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims Residual albuminuria remains a major clinical challenge in patients with type 2 diabetes mellitus and hypertension despite renin–angiotensin system inhibitor therapy. Esaxerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, reduces albuminuria; however, its effects on oxidative stress remain unclear.
Makoto Ohara, Takemasa Omachi, Nobuaki Takehana, Tomoki Fujikawa, Naoya Osaka, Shunichiro Irie, Michishige Terasaki, Yusaku Mori, Takanori Matsui, Sho‐ichi Yamagishi   +9 more
wiley   +1 more source

Correction: The mineralocorticoid receptor antagonist finerenone enhances cardiovascular recovery upon food intake normalization in obese mice. [PDF]

Cardiovasc Diabetol
Monmirel-Fauconnier M, Pieronne-Deperrois M, Bonnard B, Frimat C, Linghui K, Dheasmhunaigh AN, Nicol L, Morchid S, Renet S, Dumesnil A, Richard V, Fève B, Jaisser F, Boulkroun S, Mulder P, Ouvrard-Pascaud A.   +15 more
europepmc   +1 more source

Temporal distribution of acute kidney injury–related hospitalizations after initiation of sodium–glucose cotransporter 2 inhibitors: A nationwide claims database analysis in older adults with an independent complementary single‐center eGFR analysis

Journal of Diabetes Investigation, EarlyView.
Among 190 older adults who experienced AKI‐related hospitalization after SGLT2 inhibitor initiation, 31.1% were hospitalized within 30 days. In an independent single‐center cohort, sustained early eGFR decline was associated with older age and use of one or two triple‐whammy‐related drug classes.
Kazuya Hiura, Ayana Tatsuno, Yamato Noto, Ryosuke Wakamatsu, Masayuki Sakunami, Ryu Kobayashi, Miki Yamashita   +6 more
wiley   +1 more source

The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction. [PDF]

Cardiovasc Diabetol, 2023
Kintscher U, Edelmann F.
europepmc   +1 more source

Long‐term effects of tofogliflozin on renal function in patients with type 2 diabetes: A retrospective multicenter study

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims To investigate the long‐term renal effects of tofogliflozin, with the shortest half‐life among sodium–glucose cotransporter 2 inhibitors, in real‐world clinical practice. Materials and methods We retrospectively enrolled patients with type 2 diabetes mellitus treated at three affiliated hospitals between January 2015 and May 2024.
Natsuko Shinagawa, Hiroshi Okada, Junya Hironaka, Shinta Yamamoto, Mari Yoneda, Sayaka Kawai, Yuto Saijyo, Tomoya Katayama, Hanako Nakajima, Akio Kishi, Noriyuki Kitagawa, Naoko Nakanishi, Masahide Hamaguchi, Michiaki Fukui   +13 more
wiley   +1 more source

Inpatient Cardiac Resynchronization Therapy During Heart Failure Hospitalization: A Distinct High‐Risk Phenotype

Pacing and Clinical Electrophysiology, EarlyView.
ABSTRACT Background The role of cardiac resynchronization therapy (CRT) during hospitalization for heart failure (HFH) is uncertain, because hospitalized patients were routinely excluded from landmark CRT trials. Despite this, CRT implantation during HFH is common.
Oliver Rees, James Dargan, Jemima Weir, Robin Ray, Giuseppe Rosano, Fadi Johura   +5 more
wiley   +1 more source

Potassium binders and continuation of renin-angiotensin system inhibitors/mineralocorticoid receptor antagonist in chronic kidney disease and heart failure (the DEMONSTRATE database). [PDF]

J Intern Med
Furuland H, Larsson AO, Uhde M, Parv K, Almstedt M, Cars T, Svensson MK.   +6 more
europepmc   +1 more source

Finerenone: Questions and Answers-The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist. [PDF]

J Clin Med, 2023
Di Lullo L, Lavalle C, Scatena A, Mariani MV, Ronco C, Bellasi A.   +5 more
europepmc   +1 more source

Advanced Conduction Disease After Incident Heart Failure in Myotonic Dystrophy Type 1

Pacing and Clinical Electrophysiology, EarlyView.
Central Figure. Advanced Conduction Disease After Incident HF in Myotonic Dystrophy Type 1. ABSTRACT Background Myotonic dystrophy type 1 (DM1) is associated with progressive cardiac conduction disease, heart failure (HF) and increased mortality. However, the association of incident HF with conduction disease and survival in DM1 is not well defined ...
Isadora Guarino, Lauren Elman, Gregory Supple, Saman Nazarian   +3 more
wiley   +1 more source